Cytokinetics jumps after positive Phase 3 ACACIA-HCM topline results for aficamten in non-obstructive HCM

Cytokinetics (CYTK) is up 18.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears driven by Cytokinetics’ announcement of positive topline Phase 3 ACACIA-HCM results for aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). Investors likely viewed the readout as expanding aficamten’s commercial and regulatory opportunity beyond the company’s currently approved obstructive HCM indication.

Details:

Cytokinetics said ACACIA-HCM met both dual primary endpoints, showing statistically significant improvements versus placebo at Week 36 in KCCQ-Clinical Summary Score (symptoms/quality of life) and peak VO2 (maximal exercise performance).

The company also highlighted consistent positive findings across key secondary endpoints, including NYHA functional class improvement and biomarker changes (including NT-proBNP).

On safety, Cytokinetics said no new safety signals were identified, though reduced LVEF below 50% occurred more often with aficamten than placebo, and a small number of participants experienced serious heart-failure events associated with low LVEF.

The company scheduled an investor call and webcast on May 5, 2026 to discuss the ACACIA-HCM topline results.

Sources:

Cytokinetics Investor Relations, GlobeNewswire, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CYTK Insider Trading Activity

$CYTK insiders have traded $CYTK stock on the open market 41 times in the past 6 months. Of those trades, 0 have been purchases and 41 have been sales.

Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:

ANDREW CALLOS (EVP, Chief Commercial Officer) has made 0 purchases and 18 sales selling 153,828 shares for an estimated $9,776,399.
ROBERT I BLUM (President & CEO) has made 0 purchases and 6 sales selling 67,032 shares for an estimated $4,193,547.
EDWARD M. MD KAYE has made 0 purchases and 2 sales selling 33,239 shares for an estimated $2,209,219.
FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 10 sales selling 31,835 shares for an estimated $2,005,407.
WENDELL WIERENGA sold 20,000 shares for an estimated $1,322,800
JOHN T HENDERSON sold 8,750 shares for an estimated $559,125
B LYNNE PARSHALL sold 5,000 shares for an estimated $323,650
SUNG LEE (EVP, Chief Financial Officer) sold 4,935 shares for an estimated $306,710
ROBERT ARTHUR HARRINGTON sold 2,150 shares for an estimated $143,620

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive CYTK Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$CYTK Hedge Fund Activity

We have seen 246 institutional investors add shares of $CYTK stock to their portfolio, and 183 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 9,690,092 shares (-50.8%) from their portfolio in Q4 2025, for an estimated $615,708,445
DEEP TRACK CAPITAL, LP removed 963,002 shares (-22.4%) from their portfolio in Q4 2025, for an estimated $61,189,147
BLACKROCK, INC. added 869,376 shares (+5.6%) to their portfolio in Q4 2025, for an estimated $55,240,151
VESTAL POINT CAPITAL, LP removed 725,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $46,066,500
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 718,479 shares (-75.3%) from their portfolio in Q4 2025, for an estimated $45,652,155
UBS GROUP AG removed 671,795 shares (-37.3%) from their portfolio in Q4 2025, for an estimated $42,685,854
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 565,393 shares (+151987.4%) to their portfolio in Q4 2025, for an estimated $35,925,071

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$CYTK Analyst Ratings

Wall Street analysts have issued reports on $CYTK in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Overweight" rating on 01/28/2026
Needham issued a "Buy" rating on 12/22/2025
HC Wainwright & Co. issued a "Buy" rating on 12/22/2025
Citizens issued a "Market Outperform" rating on 12/22/2025
Goldman Sachs issued a "Buy" rating on 12/19/2025
B. Riley Securities issued a "Buy" rating on 11/10/2025

To track analyst ratings and price targets for $CYTK, check out Quiver Quantitative's $CYTK forecast page.

$CYTK Price Targets

Multiple analysts have issued price targets for $CYTK recently. We have seen 14 analysts offer price targets for $CYTK in the last 6 months, with a median target of $95.0.

Here are some recent targets:

Yanan Zhu from Wells Fargo set a target price of $95.0 on 04/10/2026
Gena Wang from Barclays set a target price of $95.0 on 04/06/2026
Salim Syed from Mizuho set a target price of $100.0 on 03/18/2026
Tessa Romero from JP Morgan set a target price of $75.0 on 03/17/2026
Ashwani Verma from UBS set a target price of $69.0 on 03/06/2026
Roanna Ruiz from Leerink Partners set a target price of $84.0 on 02/26/2026
Serge Belanger from Needham set a target price of $85.0 on 02/25/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.